跳至主要内容
临床试验/NCT01684956
NCT01684956Unknown2 期

Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Volunteers With Type 1 Diabetes

Massachusetts General Hospital2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2012年8月最近更新:
适应症

试验速览

阶段
2 期
入组人数
20
试验地点
2
主要终点
Aggregate mean difference in tmax between the delivery methods (the insulin and glucagon data will be evaluated separately)

研究概览

简要总结

The investigators are doing this research study to find out if the type of needle used to administer them affects the speed with which insulin and glucagon get into the blood. The investigators will compare a traditional insulin needle to an injection device, called the MicronJet, that uses microneedles to deliver medication into the top layer of your skin.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 years or older with clinical type 1 diabetes for at least one year
  • Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting insulins including insulin aspart (Novolog), insulin lispro (Humalog), and insulin glulisine (Apidra).
  • Ability to consume a sufficient amount of carbohydrates over 2-3 hours to cover 5 units of rapid acting insulin
  • Stimulated C-peptide <0.1 nmol/L at 90 minutes after liquid mixed meal tolerance test.

排除标准

  • Unable to provide informed consent
  • Unable to comply with study procedures
  • Current participation in another diabetes-related clinical trial other than one that is primarily observational in nature. Potential subjects enrolled in trails of passive monitoring equipment, such as continuous glucose monitors (CGMs), are not excluded
  • Inadequate venous access as determined by study nurse or physician at time of screening
  • Pregnancy
  • Hemoglobin less than 13.5 for men and less than 12 for women
  • History of pheochromocytoma (fractionated metanephrines will be tested in patients with history increasing the risk for a catecholamine secreting tumor to include episodic or treatment refractory hypertension defined as requiring 4 or more medications to achieve normotension, paroxysms of tachycardia, pallor, or headache, or personal or family history of MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease)
  • History of adverse reaction to glucagon (including allergy) besides nausea and vomiting
  • History of adrenal disease or tumor
  • Hypertension (blood pressure > 160/100 mm/Hg at screening or day of study visit
  • History of allergy to aspirin or any history of aspirin intolerance, including Reye's syndrome, or gastric ulcer or bleeding associated with salicylates.
  • Blood dyscrasia or bleeding diathesis, such as hemophilia, Von Willebrand's disorder, and idiopathic thrombocytopenic purpura (ITP)
  • Peptic Ulcer

结局指标

主要结局

Aggregate mean difference in tmax between the delivery methods (the insulin and glucagon data will be evaluated separately)

时间窗: 1 day

次要结局

  • Aggregate mean difference in area under the curve (AUC) between methods(1 day)
  • AUC of 0-1 hour (and by subtraction hours 1-5)(1 day)
  • AUC of 0-2 hours (and by subtraction hours 2-5)(1 day)
  • Time to 50% of Total AUC (or said another way, time to 50% exposure)(1 day)
  • Difference in mean visual analog pain score between insulin and glucagon with subcutaneous injection(1 day)
  • Aggregate mean difference in t1/2max between the methods(1 day visit)
  • Fraction of subjects with difference in tmax between the methods of > 25%(1 day)
  • Fraction of "dry" injections with no reflux of fluid from the injection site(1 day)
  • Aggregate mean difference in Cmax between the methods(1 day)
  • Difference in mean visual analog pain score between the two methods(1 day)
  • Difference in mean visual analog pain score between insulin and glucagon with intradermal injection(1 day)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Steven J. Russell, MD, PhD

Associate Professor

Massachusetts General Hospital

研究点 (2)

Loading locations...

相似试验